Bioelectrical Impedance Phase Angle in Predicting Treatment Outcome in Patients With Extensive Stage Small Cell Lung Cancer Receiving First-Line Chemotherapy

Inclusion Criteria: * A primary histopathological and/or cytopathological diagnosis of small cell lung cancer (SCLC) * Diagnosis of extensive stage disease (extensive stage \[ES\]-SCLC), with stage established by computed tomography (CT), magnetic resonance imaging (MRI), or positron emission tomography (PET) scan * Scheduled to receive front-line platinum-based chemotherapy with carboplatin or cisplatin plus etoposide * Ability to understand and the willingness to sign an institutional review board (IRB)-approved informed consent document Exclusion Criteria: * No recent chemotherapy or surgery, as defined as in the last 6 months * Presence of a pacemaker or defibrillator * Patients with major chronic disease known to adversely affect PA, including human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS), congestive heart failure, tuberculosis * Patients with body mass index (BMI) greater than 34 or less than 16 * Any condition or abnormality which may, in the opinion of the investigator, compromise the safety of patients * Unable or unwilling to follow protocol requirements * Pregnant women are excluded from participation due to inability to participate in required chemotherapy regimen